Melanomas with mutations in NRAS, the second most prevalent mutated proto-oncogene in melanoma, are characteristically more aggressive and susceptible to developing resistance to treatment when compared to BRAF mutants [2,5]. This evidence concerns the gene NRAS and melanoma.